

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 September 2020 (17.09.2020)



(10) International Publication Number
WO 2020/185640 A1

(51) International Patent Classification:

C07C 309/65 (2006.01) A61K 38/00 (2006.01)
A61K 33/243 (2019.01) G01N 33/50 (2006.01)
A61K 31/336 (2006.01) C12Q 1/00 (2006.01)
A61P 35/00 (2006.01)

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2020/021615

(22) International Filing Date:

08 March 2020 (08.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/815,762 08 March 2019 (08.03.2019) US

(71) Applicant: LANTERN PHARMA INC. [US/US]; 920 McKinney Avenue, 7th Floor, Dallas, TX 75201 (US).

(72) Inventors: KULKAMI, Aditya; 920 McKinney Avenue, Dallas, TX 75201 (US). ASAITHAMBI, Arun; 920 McKinney Avenue, Dallas, TX 75201 (US).

(74) Agent: ACHARYA, Nigamnarayan; Lewis Brisbois Bisgaard & Smith LLP, 1180 Peachtree Street NE, Suite 2800, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER




FIG. 2

(57) Abstract: A method of treating a female patient suffering from non-small cell lung cancer includes the step of administering to the patient in need thereof a composition of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof. The method can include other primary line therapies.

WO 2020/185640 A1